We are very disappointed to report that the NICE single technology appraisal of avapritinib (Ayvakit) for the treatment of unresectable or metastatic PDGFRA D842V-mutant GIST has been terminated. PDGFRA D842V-mutant GIST is an ultra-rare form of GIST affecting 5-10 newly diagnosed GIST cancer patients each year in the UK. After a significant amount of work […]
Continue reading
avapritinib